Background
==========

Soft tissue sarcomas (STS) are rare mesenchymal tumours originating from visceral and connective tissue. This group of tumours accounts for approximately one percent of all malignancies and consists of more than 50 histological subtypes \[[@B1]\]. The only curative treatment is surgical resection with large margins with or without adjuvant radiotherapy \[[@B1]\]. Treatment for locally advanced and metastatic disease is usually palliative and was until recently mostly confined to anthracyclin or ifosfamide based chemotherapy, apart from specific chemotherapy regimens used for specific subgroups \[[@B1]\]. Reported response rates vary between 16-27% and median survival is reported to be 12 months \[[@B2]\]. Trabectedin was introduced recently for STS, mainly for patients with (myxoid) lipo- and leiomyosarcomas \[[@B3],[@B4]\].

More recently, the phase III PALETTE study \[[@B5]\] introduced pazopanib (Votrient®) as treatment for adult patients with non-lipomatous advanced STS who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. This was based on a progression free survival of 4.6 months for pazopanib versus 1.6 months in the placebo arm. Pazopanib is an oral anti-angiogenic multi-targeted tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3, platelet derived growth factor receptors and KIT. In the PALETTE study, treatment with pazopanib was complicated by the occurrence of a pneumothorax in 8 of the 246 patients. This case series reports on the incidence and clinic of this complication in all consecutive patients treated at the Leiden University Medical Centre.

Cases
=====

In our institution, 43 STS patients were treated with pazopanib, of which 39 had pulmonary metastases and 36 of these patients had pleural or subpleural pulmonary metastases. Treatment was complicated by a pneumothorax in six (14.0%) patients.The first patient is a 24-year old male, with a malignant peripheral nerve sheath tumour of the left brachial plexus, diagnosed three years before. Initial treatment consisted of local resection and irradiation, repeated one year later because of local recurrence. Pulmonary metastases, some localised pleural, were found seven months later for which six cycles of 3-weekly doxorubicin 75 mg/m2 was initiated. Progressive disease was diagnosed six months after the first doxorubicin cycle and treatment with pazopanib was started. A CT scan at the start of pazopanib showed a necrotizing metastasis in the left lung (Figure  [1](#F1){ref-type="fig"}A, B). A month later a left-sided pneumothorax occurred after a skiing trip at 3000 meters height, persisting after drainage and later also a right sided pneumothorax occurred. The CT scan detecting the pneumothorax on the left side, also showed cystic degeneration of metastases in the right lower lobe (Figure  [1](#F1){ref-type="fig"}C, D). The persistent bilateral pneumothorax was complicated by a pyothorax on the left side. He died six months after the start of pazopanib, which was continued until his death.Patient 2 is a 79-year old male, who was diagnosed two years before with an angiosarcoma of the scalp. Primary treatment was combined paclitaxel and radiotherapy. However, one year later a local recurrence was diagnosed and a CT scan showed pulmonary metastases, of which some were pleural, for which 3-weekly doxorubicin 75 mg/m2 was started. The local recurrence was progressive after six months and pazopanib was initiated, which was stopped three months thereafter because of progressive disease. Some of the pulmonary metastases already showing cavitation at start of pazopanib (Figure  [2](#F2){ref-type="fig"}A) were increasing in number, size and cavitation during treatment (Figure  [2](#F2){ref-type="fig"}B, C). One week after the start of pazopanib a right sided pneumothorax occurred (Figure  [2](#F2){ref-type="fig"}D), which was treated with drainage, but without pleurodesis, however it recurred one week later and again drained. A month thereafter a left-sided pneumothorax was diagnosed, which was left untreated. He died one week later due to disease progression, four months after the start of pazopanib.The third patient is a 34-year old male, three years before diagnosed with a synovial sarcoma of the left femur with synchronous lung metastases, some with a pleural localisation, and malignant pleural effusion. Treatment consisted of resection of the primary tumour and doxorubicin/ifosfamide chemotherapy followed by pulmonary metastasectomy and isolated melphalan lung perfusion. Treatment with trabectedin was started, but stopped after nine cycles because of progressive disease and pazopanib was started. He was treated for a remarkable 15 months when progression occurred and a hydropneumothorax was diagnosed on a routine follow-up CT scan (Figure  [3](#F3){ref-type="fig"}A, B), treated with drainage and talc pleurodesis. Pazopanib was stopped. The CT scan did not show necrotizing metastases. Two weeks later the pleural effusion recurred, and persisted until he died 2 months later.The fourth patient is a 53-year old female, who had resection of a low-grade fibromyxomatoid sarcoma of the left lower extremity 13 years before. Nine years later, pulmonary, liver and lymph node metastases were diagnosed, treated with 2 cycles of liposomal doxorubicin, which was stopped because of toxicity. Some of the pulmonary metastases were localised adjacent to the pleura. Treatment was continued with low dose doxorubicin weekly for 3 months, which was repeated one year later because of progressive disease. Three months after the last doxorubicin treatment progressive disease was diagnosed and pazopanib was prescribed. After seven months treatment with pazopanib she developed a left-sided pneumothorax (Figure  [4](#F4){ref-type="fig"}), successfully treated with drainage. No cavitation of the metastases was found. At the moment, treated for 31 months with pazopanib, she has stable disease.Patient five is a 72-year old female, who presented with a high grade undifferentiated pleomorphic sarcoma of the right lower extremity with pulmonary metastases, of which some are localised next to the pleura, one year before. She was treated with local resection, radiotherapy and 3-weekly doxorubicin 75 mg/m2. Five months after the start of doxorubicin progressive disease was diagnosed and pazopanib was prescribed (Figure  [5](#F5){ref-type="fig"}A). After two months of treatment she developed a left-sided pneumothorax, treated with drainage and pleural rubbing (Figure  [5](#F5){ref-type="fig"}B). Part of the pulmonary metastases showed cavitation. During admission a right-sided pneumothorax occurred and was drained successfully. However, she died one week later due to progressive disease.The sixth patient is a 40-year old female diagnosed with a low grade endometrial stromal sarcoma, six years before, after a uterus extirpation for uterine myomatosis. When she presented four years later with thoracic pain, CT scan of the thorax showed a large mediastinal mass and pulmonary metastases, also localised next to the pleural space. Treatment with doxorubicin was started and resulted in partial regression of the tumour masses. Eighteen months later pazopanib was started under the supervision of the reference centre because of progression of the pulmonary metastases. Due to liver toxicity the pazopanib dose was tapered to a minimum dose of 200 mg with short pauses in treatment, however treatment was successful (Figure  [6](#F6){ref-type="fig"}A, B). Treatment was permanently stopped after 33 months because of a bilateral pneumothorax and disease progression (Figure  [6](#F6){ref-type="fig"}C). She was successfully treated with drainage.

![**CT scans of patient 1. A** and **B**: CT scan of the thorax at start of pazopanib, showing a pleural metastasis of the left lung with central hypodensities suggesting necrosis (A, arrow) and showing a pulmonary metastasis in the right lung (B, arrow). **C** and **D**: CT scan, when presenting with a left-sided pneumothorax **(D)**, showing progressive hypodensity of the pleural metastasis on the left side (C, arrow) and central cavitation in the metastasis in the right lung (D, arrow).](2045-3329-4-14-1){#F1}

![**CT scans and X-thorax of patient 2. A**: CT scan at start of pazopanib showing metastases in both lungs with a large necrotizing metastasis on the left side. The pleural metastasis indicated by the arrow is also visible in **B**, which is a CT scan after 3 months of pazopanib treatment, now showing cavitations. **C** is also an image from the CT scan after 3 months of pazopanib treatment showing a metastasis (arrow) with cavitation next to the pleura. **D**: The X-thorax shows the right sided pneumothorax. The visceral pleural line is indicated by the arrow.](2045-3329-4-14-2){#F2}

![**CT scans of patient 3.** Routine follow-up CT scan showing the pneumothorax on the right side. **A** shows one of the pulmonary metastasis, **B** shows a pleural metastasis.](2045-3329-4-14-3){#F3}

![**CT scan of patient 4.** The CT scan shows the massive pulmonary metastases and a left-sided pneumothorax.](2045-3329-4-14-4){#F4}

![**CT scans of patient 5. A**: CT scan before the start of pazopanib showing multiple metastases in the right lung, one is indicated by the arrow. **B**: Routine follow-up CT scan during pazopanib treatment showing the left-sided pneumothorax and the earlier mentioned metastasis in the right lung is now showing cavitation.](2045-3329-4-14-5){#F5}

![**CT scan of patient 6. A**: CT scan at start of pazopanib showing a metastasis in the right lower lobe with a diameter of 49.6 mm. **B**: CT scan after 12 weeks of pazopanib (6 weeks of treatment and 6 weeks on hold due to liver toxicity), showing a decrease in diameter of the metastasis to 33.1 mm. **C**: CT scan showing the bilateral pneumothorax.](2045-3329-4-14-6){#F6}

Discussion
==========

The incidence of pneumothorax of 14.0% in our institution was higher than the previous reported incidence (3.3%) in the PALETTE trial \[[@B5]\]. Literature does not provide the incidence of secondary spontaneous pneumothorax in STS patients, but it is probably uncommon. Other trials with pazopanib in for example urothelial cancer, renal cell cancer, pancreatic neuroendocrine tumours and cervical cancer did not report pneumothorax as an adverse event \[[@B6]-[@B11]\]. Trials with sunitinib, another VEGFR inhibitor, in renal cell carcinoma also do not report pneumothorax as an adverse event \[[@B12],[@B13]\]. Only, two cases are published in literature of patients with a spontaneous pneumothorax during sunitinib treatment for renal cell carcinoma \[[@B14],[@B15]\]. This suggests that this is a specific adverse event in metastatic STS treated with pazopanib, however, it could still be due to underreporting in other studies or due to the natural course of this disease that predominantly metastasizes to the lungs.

One of the proposed mechanisms is necrosis of a metastasis due to therapy, resulting in a pleural defect. Another possible explanation would be a check valve mechanism due to compression of bronchioles by a lung metastasis causing hyperinflation of a lung segment and rupture of lung parenchyma \[[@B16]\]. In our patients all cases of pneumothorax were related to pleural or subpleural lung metastases, and were observed in both progressive and responding patients. Smoking is a risk factor for primary spontaneous pneumothorax, but only one of our six patients had a smoking history. We do not think smoking history is relevant for the occurrence of a pneumothorax in these patients. As with other cancer related pneumothoraxes they were difficult to treat. One of the explanations for the difficult treatment in these patients could be the use of pazopanib, which inhibits angiogenesis and thereby tissue regeneration.

A larger series is needed in a case control setting to gain more understanding of this phenomenon.

Conclusion
==========

The risk of a difficult to treat pneumothorax during pazopanib therapy should be discussed with the patient before initiation of treatment for a pulmonary metastasized sarcoma and physicians should be alert to the occurrence of such an event.
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